Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Subcutaneous Daratumumab with Standard Regimens in Multiple Myeloma (Japan)
jRCT2080223874Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, open-label trial of daratumumab in multiple myeloma (MM) (4 arms), sponsored by Janssen Pharmaceutical. Started Apr 2018; status: completed.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2080223874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223874.